These results supported the FDA-IND for our “first in human” Phase I study in adults with melanoma at the UWCCC [59], and enabled our team to conduct a Phase I trial of hu14.18-IL2 in children [60], using the same schedule used in our melanoma trial. The gene discussed is IL2; the disease is melanoma.